David Ball
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Ball has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
- Michael MacManus
Peter MacCallum Cancer Centre
9 shared publications - Shankar Siva
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Victoria, Australia
7 shared publications - Nicholas Hardcastle
Peter MacCallum Cancer Centre
6 shared publications Andrew Wirth
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
5 shared publications- Rodney John Hicks
University of Melbourne 6 Department of Medicine, St Vincent’s Hospital Fitzroy, Australia
5 shared publications - Sarah Everitt
Radiation Therapy Services, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
5 shared publications
Latest Publications
- 9 October 2024
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 68 (7) , 843-850
A cost‐effectiveness analysis of stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the management of stage 1 non‐small‐cell lung cancer: Results from the TROG 09.02 CHISEL study
Introduction: Stereotactic ablative radiotherapy (SABR) is a standard of care treatment for medically inoperable early‐stage non‐small‐cell lung cancer (NSCLC). The CHISEL trial was a phase 3 randomised controlled trial that compared SABR to conventional radiation therapy (CRT). Using patient‐level data, we compared the cost‐effectiveness of SABR and CRT for early‐stage NSCLC.Methods: Data on treatment exposure, outcomes (recurrence, survival) and quality of life (QoL; EORTC QLQ‐C30) were sourced from the trial. Quality‐adjusted life years (QALYs) were estimated for the trial period using Australian utility weights for the EORTC QLQ‐C30‐derived QLU‐C10D. Costs related to simulation, planning, delivery, verification and post‐treatment monitoring were estimated by applying Australian Medicare Benefits Schedule fees. The costs of post‐progression therapy and grade ≥3 toxicity were estimated using trial data and relevant literature sources. Cost‐effectiveness was investigated as the incremental cost per QALY gained for SABR compared to CRT.Results: Complete QoL data were available for 21 patients: 14 in the SABR arm and 7 in the CRT arm. Mean QALYs discounted at 5% per annum were similar between arms: 12.68 months for SABR and 12.12 months for CRT. The mean costs of delivering SABR and CRT were $4763 and $6817, respectively. The costs of monitoring were similar in both arms, $4856 and $4853 for SABR and CRT. The mean costs of post‐progression therapy were $24,572 for SABR and $42,801 for CRT. The mean costs of grade ≥3 toxicity were $809 in the SABR arm and $132 in the CRT arm. Therefore, the total mean cost for SABR over the period of interest was lower for SABR than CRT. Given lower mean costs and numerically higher QALYs for SABR compared with CRT, an incremental cost‐effectiveness ratio was not calculated.Conclusion: Compared to CRT, SABR is a cost‐effective treatment for early‐stage NSCLC as the estimated upfront treatment cost and the cost of subsequent care are lower for SABR for comparable mean QALYs. Assessment of the lifetime QALYs and projections of cost estimation will provide a better indication of the long‐term cost‐effectiveness of SABR.
- 9 October 2024
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 68 (7) , 843-850
A cost‐effectiveness analysis of stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the management of stage 1 non‐small‐cell lung cancer: Results from the TROG 09.02 CHISEL study
Introduction: Stereotactic ablative radiotherapy (SABR) is a standard of care treatment for medically inoperable early‐stage non‐small‐cell lung cancer (NSCLC). The CHISEL trial was a phase 3 randomised controlled trial that compared SABR to conventional radiation therapy (CRT). Using patient‐level data, we compared the cost‐effectiveness of SABR and CRT for early‐stage NSCLC.Methods: Data on treatment exposure, outcomes (recurrence, survival) and quality of life (QoL; EORTC QLQ‐C30) were sourced from the trial. Quality‐adjusted life years (QALYs) were estimated for the trial period using Australian utility weights for the EORTC QLQ‐C30‐derived QLU‐C10D. Costs related to simulation, planning, delivery, verification and post‐treatment monitoring were estimated by applying Australian Medicare Benefits Schedule fees. The costs of post‐progression therapy and grade ≥3 toxicity were estimated using trial data and relevant literature sources. Cost‐effectiveness was investigated as the incremental cost per QALY gained for SABR compared to CRT.Results: Complete QoL data were available for 21 patients: 14 in the SABR arm and 7 in the CRT arm. Mean QALYs discounted at 5% per annum were similar between arms: 12.68 months for SABR and 12.12 months for CRT. The mean costs of delivering SABR and CRT were $4763 and $6817, respectively. The costs of monitoring were similar in both arms, $4856 and $4853 for SABR and CRT. The mean costs of post‐progression therapy were $24,572 for SABR and $42,801 for CRT. The mean costs of grade ≥3 toxicity were $809 in the SABR arm and $132 in the CRT arm. Therefore, the total mean cost for SABR over the period of interest was lower for SABR than CRT. Given lower mean costs and numerically higher QALYs for SABR compared with CRT, an incremental cost‐effectiveness ratio was not calculated.Conclusion: Compared to CRT, SABR is a cost‐effective treatment for early‐stage NSCLC as the estimated upfront treatment cost and the cost of subsequent care are lower for SABR for comparable mean QALYs. Assessment of the lifetime QALYs and projections of cost estimation will provide a better indication of the long‐term cost‐effectiveness of SABR.
- 31 October 2023
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 18 (11) , S578
EP08.02-20 A Prospective Study of Gallium-68 Ventilation and Perfusion PET/CT Before, During, and After Radiotherapy in Patients with NSCLC
- 31 October 2023
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 18 (11) , S578
EP08.02-20 A Prospective Study of Gallium-68 Ventilation and Perfusion PET/CT Before, During, and After Radiotherapy in Patients with NSCLC
- 1 October 2021
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 16 (10) , S827-S828
PL04.04 Psychological Distress and Stigma for People with Lung Cancer: Time to Act
- 1 October 2021
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 16 (10) , S827-S828
PL04.04 Psychological Distress and Stigma for People with Lung Cancer: Time to Act
- Open Access
Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study
Introduction Low muscle mass and low muscle attenuation (radiodensity), reflecting increased muscle adiposity, are prevalent muscle abnormalities in people with lung cancer receiving curative intent chemoradiation therapy (CRT) or radiation therapy (RT). Currently, there is a limited understanding of the magnitude, determinants and clinical significance of these muscle abnormalities in the lung cancer CRT/RT population. The primary objective of this study is to identify the predictors of muscle abnormalities (low muscle mass and muscle attenuation) and their depletion over time in people with lung cancer receiving CRT/RT. Secondary objectives are to assess the magnitude of change in these parameters and their association with health-related quality of life, treatment completion, toxicities and survival. Methods and analysis Patients diagnosed with lung cancer and planned for treatment with CRT/RT are invited to participate in this prospective observational study, with a target of 120 participants. The impact and predictors of muscle abnormalities (assessed via CT at the third lumbar vertebra) prior to and 2 months post CRT/RT on the severity of treatment toxicities, treatment completion and survival will be assessed by examining the following variables: demographic and clinical factors, weight loss, malnutrition, muscle strength, physical performance, energy and protein intake, physical activity and sedentary time, risk of sarcopenia (Strength, Assistance in walking, Rise from a chair, Climb stairs, Falls history (SARC-F) score alone and with calf-circumference) and systemic inflammation. A sample of purposively selected participants with muscle abnormalities will be invited to take part in semistructured interviews to understand their ability to cope with treatment and explore preference for treatment strategies focused on nutrition and exercise. Ethics and dissemination The PREDICT study received ethics approval from the Human Research Ethics Committee at Peter MacCallum Cancer Centre (HREC/53147/PMCC-2019) and Deakin University (2019-320). Findings will be disseminated through peer review publications and conference presentations.
Open AccessPredicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study
Introduction Low muscle mass and low muscle attenuation (radiodensity), reflecting increased muscle adiposity, are prevalent muscle abnormalities in people with lung cancer receiving curative intent chemoradiation therapy (CRT) or radiation therapy (RT). Currently, there is a limited understanding of the magnitude, determinants and clinical significance of these muscle abnormalities in the lung cancer CRT/RT population. The primary objective of this study is to identify the predictors of muscle abnormalities (low muscle mass and muscle attenuation) and their depletion over time in people with lung cancer receiving CRT/RT. Secondary objectives are to assess the magnitude of change in these parameters and their association with health-related quality of life, treatment completion, toxicities and survival. Methods and analysis Patients diagnosed with lung cancer and planned for treatment with CRT/RT are invited to participate in this prospective observational study, with a target of 120 participants. The impact and predictors of muscle abnormalities (assessed via CT at the third lumbar vertebra) prior to and 2 months post CRT/RT on the severity of treatment toxicities, treatment completion and survival will be assessed by examining the following variables: demographic and clinical factors, weight loss, malnutrition, muscle strength, physical performance, energy and protein intake, physical activity and sedentary time, risk of sarcopenia (Strength, Assistance in walking, Rise from a chair, Climb stairs, Falls history (SARC-F) score alone and with calf-circumference) and systemic inflammation. A sample of purposively selected participants with muscle abnormalities will be invited to take part in semistructured interviews to understand their ability to cope with treatment and explore preference for treatment strategies focused on nutrition and exercise. Ethics and dissemination The PREDICT study received ethics approval from the Human Research Ethics Committee at Peter MacCallum Cancer Centre (HREC/53147/PMCC-2019) and Deakin University (2019-320). Findings will be disseminated through peer review publications and conference presentations.
- 21 July 2021
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 65 (6) , 786-795
Functional and patient‐reported changes in swallowing and voice after combined chemotherapy and radiotherapy for limited‐stage small‐cell lung cancer
Introduction: The purpose of this study was to describe the nature and impact of dysphagia and dysphonia in patients with limited‐stage small‐cell lung cancer (SCLC) before and after chemoradiation.Methods: A prospective cohort study was conducted on patients receiving chemoradiotherapy for limited‐stage SCLC. Patients received either 40, 45 or 50 Gy, commencing the second cycle of chemotherapy. Outcomes included: videofluoroscopy (VFSS) to investigate aspiration, swallowing function and oesophageal motility; oral intake limitations; patient‐reported dysphagia; and patient‐reported dysphonia. Data were collected before treatment and one, three and six months post‐treatment.Results: Twelve patients were enrolled. Oropharyngeal swallowing was safe and functional at all times. Three patients exhibited oesophageal motility disorders before treatment, and a further three post‐treatment. Oral intake was most compromised one month post‐treatment with five patients either tube dependent or eating very limited diets. At all other times patients were eating normal or near‐normal diets. Despite normal oropharyngeal swallowing on VFSS, three patients reported moderate or severe dysphagia one month post‐treatment. Three additional patients reported moderate or severe difficulties three and six months post‐treatment. Patients who reported dysphagia one month post‐treatment all received a mean and maximum oesophageal dose of ≥15.7 Gy and ≥42 Gy, respectively. Dose–response relationships were not apparent three and six months post‐treatment. Voice problems varied, with worst scores reported one month post‐treatment.Conclusions: This study identified discordance between observed swallowing function and patient‐reported problems, which has clinical implications for patient management, and highlights future research needs. Ongoing efforts to reduce mucosal toxicity in patients with lung cancer are essential.
- 21 July 2021
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 65 (6) , 786-795
Functional and patient‐reported changes in swallowing and voice after combined chemotherapy and radiotherapy for limited‐stage small‐cell lung cancer
Introduction: The purpose of this study was to describe the nature and impact of dysphagia and dysphonia in patients with limited‐stage small‐cell lung cancer (SCLC) before and after chemoradiation.Methods: A prospective cohort study was conducted on patients receiving chemoradiotherapy for limited‐stage SCLC. Patients received either 40, 45 or 50 Gy, commencing the second cycle of chemotherapy. Outcomes included: videofluoroscopy (VFSS) to investigate aspiration, swallowing function and oesophageal motility; oral intake limitations; patient‐reported dysphagia; and patient‐reported dysphonia. Data were collected before treatment and one, three and six months post‐treatment.Results: Twelve patients were enrolled. Oropharyngeal swallowing was safe and functional at all times. Three patients exhibited oesophageal motility disorders before treatment, and a further three post‐treatment. Oral intake was most compromised one month post‐treatment with five patients either tube dependent or eating very limited diets. At all other times patients were eating normal or near‐normal diets. Despite normal oropharyngeal swallowing on VFSS, three patients reported moderate or severe dysphagia one month post‐treatment. Three additional patients reported moderate or severe difficulties three and six months post‐treatment. Patients who reported dysphagia one month post‐treatment all received a mean and maximum oesophageal dose of ≥15.7 Gy and ≥42 Gy, respectively. Dose–response relationships were not apparent three and six months post‐treatment. Voice problems varied, with worst scores reported one month post‐treatment.Conclusions: This study identified discordance between observed swallowing function and patient‐reported problems, which has clinical implications for patient management, and highlights future research needs. Ongoing efforts to reduce mucosal toxicity in patients with lung cancer are essential.
- 12 July 2021
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 18 (5) , E235-E246
Lung cancer treatment patterns and factors relating to systemic therapy use in Australia
Aim: Systemic therapies for lung cancer are rapidly evolving. This study aimed to describe lung cancer treatment patterns in New South Wales, Australia, prior to the introduction of immunotherapy and latest‐generation targeted therapies.Methods: Systemic therapy utilization and treatment‐related factors were examined for participants in the New South Wales 45 and Up Study with incident lung cancer ascertained by record linkage to the New South Wales Cancer Registry (2006–2013). Systemic therapy receipt to June 2016 was determined using medical and pharmaceutical claims data from Services Australia, and in‐patient hospital records. Factors related to treatment were identified using competing risks regressions.Results: A total of 1,116 lung cancer cases were identified with a mean age at diagnosis of 72 years and median survival of 10.6 months. Systemic therapy was received by 45% of cases. Among 400 cases with metastatic non–small cell lung cancer, 51% and 28% received first‐ and second‐line systemic therapy, respectively. Among 112 diagnosed with small‐cell lung cancer, 79% and 29% received first‐ and second‐line systemic therapy. The incidence of systemic therapy was lower for participants with indicators of poor performance status, lower educational attainment, and those who lived in areas of socioeconomic disadvantage; and was higher for participants with small‐cell lung cancer histology or higher body mass index.Conclusion: This population‐based Australian study identified patterns of systemic therapy use for lung cancer, particularly small‐cell lung cancer. Despite a universal healthcare system, the analysis revealed socioeconomic disparities in health service utilization and relatively low utilization of systemic therapy overall.
- 12 July 2021
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 18 (5) , E235-E246
Lung cancer treatment patterns and factors relating to systemic therapy use in Australia
Aim: Systemic therapies for lung cancer are rapidly evolving. This study aimed to describe lung cancer treatment patterns in New South Wales, Australia, prior to the introduction of immunotherapy and latest‐generation targeted therapies.Methods: Systemic therapy utilization and treatment‐related factors were examined for participants in the New South Wales 45 and Up Study with incident lung cancer ascertained by record linkage to the New South Wales Cancer Registry (2006–2013). Systemic therapy receipt to June 2016 was determined using medical and pharmaceutical claims data from Services Australia, and in‐patient hospital records. Factors related to treatment were identified using competing risks regressions.Results: A total of 1,116 lung cancer cases were identified with a mean age at diagnosis of 72 years and median survival of 10.6 months. Systemic therapy was received by 45% of cases. Among 400 cases with metastatic non–small cell lung cancer, 51% and 28% received first‐ and second‐line systemic therapy, respectively. Among 112 diagnosed with small‐cell lung cancer, 79% and 29% received first‐ and second‐line systemic therapy. The incidence of systemic therapy was lower for participants with indicators of poor performance status, lower educational attainment, and those who lived in areas of socioeconomic disadvantage; and was higher for participants with small‐cell lung cancer histology or higher body mass index.Conclusion: This population‐based Australian study identified patterns of systemic therapy use for lung cancer, particularly small‐cell lung cancer. Despite a universal healthcare system, the analysis revealed socioeconomic disparities in health service utilization and relatively low utilization of systemic therapy overall.
- Open Access
Monitoring DNA Damage and Repair in Peripheral Blood Mononuclear Cells of Lung Cancer Radiotherapy Patients
Thoracic radiotherapy (RT) is required for the curative management of inoperable lung cancer, however, treatment delivery is limited by normal tissue toxicity. Prior studies suggest that using radiation-induced DNA damage response (DDR) in peripheral blood mononuclear cells (PBMC) has potential to predict RT-associated toxicities. We collected PBMC from 38 patients enrolled on a prospective clinical trial who received definitive fractionated RT for non-small cell lung cancer. DDR was measured by automated counting of nuclear γ-H2AX foci in immunofluorescence images. Analysis of samples collected before, during and after RT demonstrated the induction of DNA damage in PBMC collected shortly after RT commenced, however, this damage repaired later. Radiation dose to the tumour and lung contributed to the in vivo induction of γ-H2AX foci. Aliquots of PBMC collected before treatment were also irradiated ex vivo, and γ-H2AX kinetics were analyzed. A trend for increasing of fraction of irreparable DNA damage in patients with higher toxicity grades was revealed. Slow DNA repair in three patients was associated with a combined dysphagia/cough toxicity and was confirmed by elevated in vivo RT-generated irreparable DNA damage. These results warrant inclusion of an assessment of DDR in PBMC in a panel of predictive biomarkers that would identify patients at a higher risk of toxicity.
Open AccessMonitoring DNA Damage and Repair in Peripheral Blood Mononuclear Cells of Lung Cancer Radiotherapy Patients
Thoracic radiotherapy (RT) is required for the curative management of inoperable lung cancer, however, treatment delivery is limited by normal tissue toxicity. Prior studies suggest that using radiation-induced DNA damage response (DDR) in peripheral blood mononuclear cells (PBMC) has potential to predict RT-associated toxicities. We collected PBMC from 38 patients enrolled on a prospective clinical trial who received definitive fractionated RT for non-small cell lung cancer. DDR was measured by automated counting of nuclear γ-H2AX foci in immunofluorescence images. Analysis of samples collected before, during and after RT demonstrated the induction of DNA damage in PBMC collected shortly after RT commenced, however, this damage repaired later. Radiation dose to the tumour and lung contributed to the in vivo induction of γ-H2AX foci. Aliquots of PBMC collected before treatment were also irradiated ex vivo, and γ-H2AX kinetics were analyzed. A trend for increasing of fraction of irreparable DNA damage in patients with higher toxicity grades was revealed. Slow DNA repair in three patients was associated with a combined dysphagia/cough toxicity and was confirmed by elevated in vivo RT-generated irreparable DNA damage. These results warrant inclusion of an assessment of DDR in PBMC in a panel of predictive biomarkers that would identify patients at a higher risk of toxicity.
- Open Access
TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival
Lung cancer poses the greatest cancer-related death risk and males have poorer outcomes than females, for unknown reasons. Patient sex is not a biological variable considered in lung cancer standard of care. Correlating patient genetics with outcomes is predicted to open avenues for improved management. Using a bioinformatics approach across non-small cell lung cancer (NSCLC) subtypes, we identified where patient sex, mutation of the major tumor suppressor gene, Tumour protein P53 (TP53), and immune signatures stratified outcomes in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), among datasets of The Cancer Genome Atlas (TCGA). We exposed sex and TP53 gene mutations as prognostic for LUAD survival. Longest survival in LUAD occurred among females with wild-type (wt) TP53 genes, high levels of immune infiltration and enrichment for pathway signatures of Interferon Gamma (INF-γ), Tumour Necrosis Factor (TNF) and macrophages-monocytes. In contrast, poor survival in men with LUAD and wt TP53 genes corresponded with enrichment of Transforming Growth Factor Beta 1 (TGFB1, hereafter TGF-β) and wound healing signatures. In LUAD with wt TP53 genes, elevated gene expression of immune checkpoint CD274 (hereafter: PD-L1) and also protein 53 (p53) negative-regulators of the Mouse Double Minute (MDM)-family predict novel avenues for combined immunotherapies. LUSC is dominated by male smokers with TP53 gene mutations, while a minor population of TCGA LC patients with wt TP53 genes unexpectedly had the poorest survival, suggestive of a separate etiology. We conclude that advanced approaches to LUAD and LUSC therapy lie in the consideration of patient sex, TP53 gene mutation status and immune signatures.
Open AccessTP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival
Lung cancer poses the greatest cancer-related death risk and males have poorer outcomes than females, for unknown reasons. Patient sex is not a biological variable considered in lung cancer standard of care. Correlating patient genetics with outcomes is predicted to open avenues for improved management. Using a bioinformatics approach across non-small cell lung cancer (NSCLC) subtypes, we identified where patient sex, mutation of the major tumor suppressor gene, Tumour protein P53 (TP53), and immune signatures stratified outcomes in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), among datasets of The Cancer Genome Atlas (TCGA). We exposed sex and TP53 gene mutations as prognostic for LUAD survival. Longest survival in LUAD occurred among females with wild-type (wt) TP53 genes, high levels of immune infiltration and enrichment for pathway signatures of Interferon Gamma (INF-γ), Tumour Necrosis Factor (TNF) and macrophages-monocytes. In contrast, poor survival in men with LUAD and wt TP53 genes corresponded with enrichment of Transforming Growth Factor Beta 1 (TGFB1, hereafter TGF-β) and wound healing signatures. In LUAD with wt TP53 genes, elevated gene expression of immune checkpoint CD274 (hereafter: PD-L1) and also protein 53 (p53) negative-regulators of the Mouse Double Minute (MDM)-family predict novel avenues for combined immunotherapies. LUSC is dominated by male smokers with TP53 gene mutations, while a minor population of TCGA LC patients with wt TP53 genes unexpectedly had the poorest survival, suggestive of a separate etiology. We conclude that advanced approaches to LUAD and LUSC therapy lie in the consideration of patient sex, TP53 gene mutation status and immune signatures.
- 1 June 2020
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 64 (3) , 462-463
Radiation oncology trainee research requirements - re-thinking our intention and approach
- 1 June 2020
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 64 (3) , 462-463
Radiation oncology trainee research requirements - re-thinking our intention and approach
- 11 May 2020
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 64 (4) , 556-562
Does institutional patient accrual volume impact overall survival in patients with inoperable non‐small‐cell lung cancer receiving radical (chemo)radiation? A secondary analysis of TROG 99.05
Introduction: Increased hospital patient volume, reflecting greater experience, has been shown to be associated with improved survival for some cancers. However, there is no evidence to support the volume–outcome hypothesis for inoperable non‐small‐cell lung cancer (NSCLC) patients within the Australasian setting. We examined the relationship between overall survival (OS) and institutional patient accrual volume (IPAV) in a large prospective Australasian NSCLC database (TROG 99.05).Methods: TROG 99.05 was an observational study which accrued patients from 1999 to 2007 to examine the relationship between primary lung cancer volume and survival. To be eligible for inclusion, patients had to have inoperable, biopsy‐proven NSCLC planned for radiotherapy to a minimum dose of 50Gy in 20 fractions, with or without chemotherapy. Participating institutions were de‐identified and grouped according to whether accrual was low, medium or high. OS was compared between groups and adjusted for prognostic factors using Cox regression.Results: About 509 patients were accrued from 16 centres. Median potential follow‐up time was 60 months. Median survival for all groups was 20 months (95% CI 18.3–21.8 months). There were no statistically significant differences in OS with increasing patient accrual across the three groups after adjustment for prognostic factors (P = 0.84, 2 df). The hazard ratios (HR) for group accrual volumes, relative to that for high‐accrual volume, were as follows: low, 1.18; medium, 1.14. Test for trend: HR = 0.91 per group (95% CI 0.76–1.09, P = 0.31).Conclusion: In the setting of a clinical trial with rigorous quality assurance, we found no evidence for an association between institutional accrual and survival.
- 11 May 2020
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 64 (4) , 556-562
Does institutional patient accrual volume impact overall survival in patients with inoperable non‐small‐cell lung cancer receiving radical (chemo)radiation? A secondary analysis of TROG 99.05
Introduction: Increased hospital patient volume, reflecting greater experience, has been shown to be associated with improved survival for some cancers. However, there is no evidence to support the volume–outcome hypothesis for inoperable non‐small‐cell lung cancer (NSCLC) patients within the Australasian setting. We examined the relationship between overall survival (OS) and institutional patient accrual volume (IPAV) in a large prospective Australasian NSCLC database (TROG 99.05).Methods: TROG 99.05 was an observational study which accrued patients from 1999 to 2007 to examine the relationship between primary lung cancer volume and survival. To be eligible for inclusion, patients had to have inoperable, biopsy‐proven NSCLC planned for radiotherapy to a minimum dose of 50Gy in 20 fractions, with or without chemotherapy. Participating institutions were de‐identified and grouped according to whether accrual was low, medium or high. OS was compared between groups and adjusted for prognostic factors using Cox regression.Results: About 509 patients were accrued from 16 centres. Median potential follow‐up time was 60 months. Median survival for all groups was 20 months (95% CI 18.3–21.8 months). There were no statistically significant differences in OS with increasing patient accrual across the three groups after adjustment for prognostic factors (P = 0.84, 2 df). The hazard ratios (HR) for group accrual volumes, relative to that for high‐accrual volume, were as follows: low, 1.18; medium, 1.14. Test for trend: HR = 0.91 per group (95% CI 0.76–1.09, P = 0.31).Conclusion: In the setting of a clinical trial with rigorous quality assurance, we found no evidence for an association between institutional accrual and survival.